ARTICLE | Company News
Columbia Laboratories, Invaron Pharmaceuticals sales and marketing update
August 1, 2011 7:00 AM UTC
Columbia granted Invaron Canadian commercialization rights to Striant testosterone buccal system. The buccal testosterone tablets are approved in the U.S. for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone. Invaron is responsible for regulatory approval. Columbia is eligible for royalties. Terms were not disclosed. ...